Ten-year mortality trends among persons diagnosed with HIV infection in England and Wales in the era of antiretroviral therapy: AIDS remains a silent killer

HIV Medicine

Volumn 14, Issue 10, 2013, Pages 596-604

  Simmons, R D ^a   Ciancio, B C ^b   Kall, M M ^a   Rice, B D ^a   Delpech, V C ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

Author keywords

AIDS; HIV; Late diagnosis; Mortality

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANTIVIRAL THERAPY; ARTICLE; ATTRIBUTABLE RISK; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DYING; EARLY DIAGNOSIS; FEMALE; GROUPS BY AGE; HETEROSEXUALITY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; UNITED KINGDOM;

AIDS; HIV; LATE DIAGNOSIS; MORTALITY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGE FACTORS; CASE-CONTROL STUDIES; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DELAYED DIAGNOSIS; ENGLAND; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MORTALITY; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 84885484873     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12045     Document Type: Article

References (41)

1. Bhaskaran K, Hamouda O, Sannes M etal. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008; 300: 51-59.
2. Crum NF, Riffenburgh RH, Wegner S etal. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006; 41: 194-200.
3. Martinez E, Milinkovic A, Buira E etal. Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area. HIV Med 2007; 8: 251-258.
4. Palella FJ Jr, Baker RK, Moorman AC etal. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27-34.
5. Smit C, Geskus R, Walker S etal. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006; 20: 741-749.
6. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372: 293-299.
7. Lohse N, Hansen AB, Pedersen G etal. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146: 87-95.
8. May M, Gompels M, Delpech V etal. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ 2011; 343: d6016.
9. Nakagawa F, Lodwick RK, Smith CJ etal. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2012; 26: 335-343.
10. Bonnet F, Morlat P, Chene G etal. Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999. HIV Med 2002; 3: 195-199.
11. Health Protection Agency. United Kingdom New HIV diagnoses to end of December 2011. 2012. Available at www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1237970242135 (accessed 6 May 2013).
12. Health Protection Agency. New HIV diagnoses. 2012. Available at www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/HIV/NewHIVDiagnoses/ (accessed 5 July 2012).
13. Health Protection Agency. Numbers receiving HIV care. 2012. Available at www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/HIV/AccessingHIVCare/ (accessed 5 July 2012).
14. Health Protection Agency. CD4 surveillance. 2012. Available at www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/HIV/CD4TcellData/ (accessed 5 July 2012).
15. Rice BD, Delpech VC, Chadborn TR, Elford J. Loss to follow-up among adults attending human immunodeficiency virus services in England, Wales, and Northern Ireland. Sex Transm Dis 2011; 38: 685-690.
16. Ancelle-Park RA. Expanded European AIDS case definition. Lancet 1993; 341: 441.
17. The Office for National Statistics. Mortality statistics deaths registered in 2008. 2009. Available at www.ons.gov.uk/ons/rel/vsob1/mortality-statistics-deaths-registered-in-england-and-wales-series-dr-/2008/index.html (accessed 10 July 2012).
18. Bargagli AM, Hickman M, Davoli M etal. Drug-related mortality and its impact on adult mortality in eight European countries. Eur J Public Health 2006; 16: 198-202.
19. Gossop M, Stewart D, Treacy S, Marsden J. A prospective study of mortality among drug misusers during a 4-year period after seeking treatment. Addiction 2002; 97: 39-47.
20. Hickman M, Hope V, Coleman B etal. Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action. J Public Health (Oxf) 2009; 31: 374-382.
21. Oppenheimer E, Tobutt C, Taylor C, Andrew T. Death and survival in a cohort of heroin addicts from London clinics: a 22-year follow-up study. Addiction 1994; 89: 1299-1308.
22. Robertson JR, Ronald PM, Raab GM, Ross AJ, Parpia T. Deaths, HIV infection, abstinence and other outcomes in a cohort of injecting drug users followed up for 10 years. BMJ 1994; 309: 369-372.
23. Wille R. Ten-year follow-up of a representative sample of London heroin addicts: clinic attendance, abstinence and mortality. Br J Addict 1981; 76: 259-266.
24. Bewley TH, Ben-Arie O. Morbidity and mortality from heroin dependence. 2. Study of 100 consecutive patients. BMJ 1968; 1: 727-730.
25. Lewden C, Salmon D, Morlat P etal. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34: 121-130.
26. Sabin CA, Smith CJ, Youle M etal. Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. AIDS 2006; 20: 67-71.
27. Sabin CA, Smith CJ, Gumley H etal. Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS 2004; 18: 2145-2151.
28. Chadborn TR, Delpech VC, Sabin CA, Sinka K, Evans BG. The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000-2004). AIDS 2006; 20: 2371-2379.
29. Chadborn TR, Baster K, Delpech VC etal. No time to wait: how many HIV-infected homosexual men are diagnosed late and consequently die? (England and Wales, 1993-2002). AIDS 2005; 19: 513-520.
30. Egger M, May M, Chene G etal. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119-129.
31. Chene G, Sterne JA, May M etal. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003; 362: 679-686.
32. Young J, Psichogiou M, Meyer L etal. CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med 2012; 9: e1001194.
33. Smith RD, Delpech VC, Brown AE, Rice BD. HIV transmission and high rates of late diagnoses among adults aged 50 years and over. AIDS 2010; 24: 2109-2115.
34. Health Protection Agency. HIV in the United Kingdom: 2012 Report 2012. Available at www.hpa.org.uk/Publications/InfectiousDiseases/HIVAndSTIs/1211HIVintheUK2012/ (accessed 13 February 2013).
35. Burns FM, Johnson AM, Nazroo J etal. Missed opportunities for earlier HIV diagnosis within primary and secondary healthcare settings in the UK. AIDS 2008; 22: 115-122.
36. British HIV Association, British Association for Sexual Health and HIV, British Infection Society. UK national guidelines for HIV testing 2008. British HIV Association; 2008. Available at www.bhiva.org/HIVTesting2008.aspx (accessed 13 February 2013).
37. National Institute for Health and Clinical Excellence. Increasing the uptake of HIV testing among black Africans in England. NICE; 2011. Available at: http://publications.nice.org.uk/increasing-the-uptake-of-hiv-testing-among-black-africans-in-england-ph33 (accessed 13 February 2013).
38. National Institute for Health and Clinical Excellence. Increasing the uptake of HIV testing among men who have sex with men. 2011. Available at: http://guidance.nice.org.uk/PH34 (accessed 13 February 2013).
39. Antinori A, Coenen T, Costagiola D etal. Late presentation of HIV infection: a consensus definition. HIV Med 2011; 12: 61-64.
40. Kowalska JD, Friis-Moller N, Kirk O etal. The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. Epidemiology 2011; 22: 516-523.
41. Hernando V, Sobrino-Vegas P, Burriel MC etal. Differences in the causes of death of HIV-positive patients in a cohort study by data sources and coding algorithms. AIDS 2012; 26: 1829-1834.